← All companiesRUltragenyx Pharmaceutical Inc.
RARE - CIK 0001515673
Ultragenyx Pharmaceutical Inc. net income by year
Ultragenyx Pharmaceutical Inc. (RARE) reported net income of -$575.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
RARE annual net income
RARE net income 2012-2025
| Fiscal year | Net Income | Change |
|---|
| FY 2025 | -$575.00M | -1.1% |
| FY 2024 | -$569.00M | +6.3% |
| FY 2023 | -$607.00M | +14.2% |
| FY 2022 | -$707.42M | -55.8% |
| FY 2021 | -$454.02M | -143.4% |
| FY 2020 | -$186.57M | +53.7% |
| FY 2019 | -$402.73M | -103.8% |
| FY 2018 | -$197.61M | +34.6% |
| FY 2017 |
Net Income of similar companies
Frequently asked questions
How much profit does Ultragenyx Pharmaceutical Inc. make?
Ultragenyx Pharmaceutical Inc. (RARE) reported net income of -$575.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
How has Ultragenyx Pharmaceutical Inc.'s net income changed over time?
Between fiscal 2012 and fiscal 2025, Ultragenyx Pharmaceutical Inc.'s net income declined from -$16.33M to -$575.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.